Kynurenine/Tryptophan ratio
|
Basic information |
| Metabolite name | Kynurenine/Tryptophan ratio |
 | N/A |
 |
N/A |
 |
N/A |
| Synonyms | kynurenine/ tryptophan; |
| No. of studies | 38 |
|
Basic information |
| Metabolite name | Kynurenine/Tryptophan ratio |
| N/A |
|
N/A |
|
N/A |
| Synonyms | kynurenine/ tryptophan; |
| No. of studies | 38 |
|
Relationship between Kynurenine/Tryptophan ratio and depression (count: 38) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M079 | Type1 | acute LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M079 | Type1 | prolonged LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M1029 | Type1 | Crohn’s disease model group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1029 | Type2 | Crohn’s disease model + moxibustion + 1-methyltryptophan group vs. Crohn’s disease model group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1029 | Type2 | Crohn’s disease model + 1-methyltryptophan group vs. Crohn’s disease model group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1029 | Type2 | Crohn’s disease model + moxibustion group vs. Crohn’s disease model group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1033 | Type1 | small intestinal bacterial overgrowth and chronic constipation group vs. control group | Urine | Human | Up |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic diarrhea group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic constipation group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M1035 | Type2 | mood disorder group, after tryptophan-rich diet vs. baseline | Urine | Human | Down |
| Study M1051 | Type1 | tumor-bearing group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M1051 | Type2 | tumor-bearing + epacadostat group vs. tumor-bearing group | Serum | C57BL/6J mouse | Down |
| Study M1081 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1081 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1081 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Brain | C57BL/6 J mouse | Down |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Serum | C57BL/6 J mouse | Down |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Colon | C57BL/6 J mouse | Down |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Brain | C57BL/6 J mouse | Down |
| Study M1082 | Type1 | interferon gamma group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M1082 | Type1 | interferon gamma group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1082 | Type1 | interferon gamma group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Colon | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Serum | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Brain | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Colon | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Brain | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Serum | C57BL/6 J mouse | Down |
| Study M1083 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M1083 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1083 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Colon | C57BL/6 J mouse | Down |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Serum | C57BL/6 J mouse | Down |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Brain | C57BL/6 J mouse | Down |
| Study M1084 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1084 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1084 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Colon | C57BL/6 J mouse | Down |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Serum | C57BL/6 J mouse | Down |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Brain | C57BL/6 J mouse | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M142 | Type1 | SNI group vs. control group | Plasma | C57/BL6J mouse | Up |
| Study M153 | Type1 | LPS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M171 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M171 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M171 | Type2 | CUMS + DXS group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M172 | Type1 | postpartum depression group vs. postpartum group | Serum | Human | Down |
| Study M184 | Type1 | depressed group vs. control group | Ventrolateral prefrontal cortex | Human | Down |
| Study M200 | Type1 | current MDD group vs. no current MDD group | Plasma | Human | Down |
| Study M470 | Type1 | rMDD group vs. control group | Plasma | Human | Up |
| Study M489 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M493 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M513 | Type1 | male MDD group vs. male HC group | Serum | Human | Up |
| Study M513 | Type1 | female MDD group vs. female HC group | Serum | Human | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M522 | Type2 | CUMS + NaP group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M524 | Type1 | hydrocortisone group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M524 | Type2 | hydrocortisone + Tiansi Liquid group vs. hydrocortisone group | Plasma | Sprague-Dawley rat | Down |
| Study M542 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M542 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M596 | Type1 | elderly depression group vs. elderly control group | Urine | Human | Up |
| Study M657 | Type4 | escitalopram-treated MDD group, responder vs. non-responder | Plasma | Human | Down |
| Study M666 | Type1 | late-life depression group vs. control group | Serum | Human | Up |
| Study M728 | Type1 | CRS group vs. control group | Hippocampus | C57BL/6 J mouse | Up |
| Study M728 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M728 | Type1 | CRS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M728 | Type1 | CRS group vs. control group | Prefrontal cortex | C57BL/6 J mouse | Up |
| Study M728 | Type1 | CRS group vs. control group | Ileum | C57BL/6 J mouse | Up |
| Study M728 | Type2 | CRS + citalopram group vs. CRS group | Prefrontal cortex | C57BL/6 J mouse | Down |
| Study M728 | Type2 | CRS + citalopram group vs. CRS group | Colon | C57BL/6 J mouse | Down |
| Study M729 | Type2 | CRS + 1-methyl-tryptophan group vs. CRS group | Hippocampus | C57BL/6 J mouse | Down |
| Study M823 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M823 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M823 | Type2 | CUMS + albiflorin group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M823 | Type2 | CUMS + albiflorin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M829 | Type1 | CUMS group vs. control group | Brain | C57BL/6J mouse | Up |
| Study M829 | Type1 | CUMS group vs. control group | Colon | C57BL/6J mouse | Up |
| Study M829 | Type1 | CUMS group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M829 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Chaihu Shugan Powder group vs. CUMS group | Liver | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Sini Powder group vs. CUMS group | Liver | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Chaihu Shugan Powder group vs. CUMS group | Brain | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Xiaoyao Powder group vs. CUMS group | Colon | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Xiaoyao Powder group vs. CUMS group | Liver | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Xiaoyao Powder group vs. CUMS group | Brain | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Sini Powder group vs. CUMS group | Colon | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Chaihu Shugan Powder group vs. CUMS group | Colon | C57BL/6J mouse | Down |
| Study M829 | Type2 | CUMS + Sini Powder group vs. CUMS group | Brain | C57BL/6J mouse | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M913 | Type2 | responder group vs. nonresponder group, at baseline | Plasma | Human | Down |
| Study M976 | Type1 | small intestinal bacterial overgrowth group vs. control group | Urine | Human | Up |
| Study M976 | Type2 | small intestinal bacterial overgrowth group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M979 | Type1 | acute myocardial infarction group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M979 | Type2 | acute myocardial infarction + ABR-215757 group vs. acute myocardial infarction group | Hippocampus | Sprague-Dawley rat | Down |
| Study M983 | Type2 | adolescent MDD group, post-treatment vs. baseline | Plasma | Human | Up |
| Study M991 | Type1 | lipopolysaccharide group vs. control group | Serum | C57Bl/6J mouse | Up |
| Study M991 | Type2 | lipopolysaccharide + 1-methyl-tryptophan group vs. lipopolysaccharide group | Serum | C57Bl/6J mouse | Down |
| Study M992 | Type1 | pilocarpine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M992 | Type2 | pilocarpine + minocycline group vs. pilocarpine group | Hippocampus | Wistar rat | Down |
| Study M992 | Type2 | pilocarpine + 1-methyltryptophan group vs. pilocarpine group | Hippocampus | Wistar rat | Down |
| Study M996 | Type1 | CUMS group vs. control group | Serum | C57BL/6J mouse | Up |